Men often explore testosterone replacement therapy (TRT) to address low levels of testosterone and associated symptoms. During treatment, a portion of testosterone undergoes conversion to estradiol. This enzymatic process is sometimes managed with additional medications, yet estradiol itself supports important functions when kept within appropriate ranges. Clear information on the physiology, documented benefits, and risks of over-suppression helps guide discussions with clinicians.
The Conversion Process
The enzyme aromatase (CYP19A1) converts testosterone to estradiol through three successive hydroxylation reactions called aromatization. This occurs mainly in adipose tissue and skeletal muscle, with a smaller direct contribution from the testes (approximately 20% of circulating estradiol) and lesser activity in bone and brain. Daily production of estradiol in adult men averages 35–45 micrograms, much of it arising from peripheral conversion of testicular and adrenal androgens. Higher body fat can increase aromatase activity and therefore the conversion rate. Circulating estradiol concentrations remain far lower than testosterone levels—roughly 1/200th—yet stay biologically active.
Estradiol’s Role When Levels Remain Appropriate
Estradiol functions as an active hormone in men rather than a simple byproduct. When conversion keeps levels in typical reference ranges (commonly cited around 10–40 pg/mL, with targets individualized), it participates in gonadotropin feedback and tissue-specific actions via estrogen receptors found in multiple male systems. Issues arise primarily when levels rise high enough to produce noticeable effects such as breast tissue sensitivity or fluid retention. In moderate amounts, estradiol contributes to normal physiology without those responses.
Documented Benefits, With Focus on Bone Health
Human research demonstrates estradiol’s contribution to skeletal maintenance in men. It helps regulate bone remodeling by limiting excessive osteoclast activity while supporting balanced formation. Men with aromatase deficiency show reduced bone mineral density, delayed epiphyseal closure, and elevated bone turnover; estradiol replacement improves density and normalizes maturation. Clinical data in older men associate lower bioavailable estradiol with faster bone loss and higher fracture risk, independent of testosterone in several analyses. Testosterone replacement improves bone mineral density in hypogonadal men, and evidence indicates that part of this skeletal benefit occurs through aromatization to estradiol.
Additional controlled studies link adequate estradiol to favorable effects on body composition (particularly fat mass) and sexual function parameters, including desire and erectile capacity, when testosterone is sufficient. Some investigations also point to a role in cardiovascular modulation, where conversion of testosterone to estradiol may mediate certain observed vascular effects.
Consequences of Excessive Suppression via Aromatase Inhibitors
Aromatase inhibitors (for example, anastrozole) are sometimes used during TRT, either routinely or when estradiol readings appear elevated. While short-term, symptom-directed use can address clear high-estradiol effects such as nipple sensitivity or marked water retention, routine or aggressive dosing often drives estradiol below ranges associated with optimal function.
Observed consequences include joint discomfort and stiffness, reductions in sexual desire and erectile function even with high testosterone, mood shifts toward irritability or lowered affect, and increased bone turnover that can reduce density over time. Reviews of aromatase inhibitor use in men note skeletal considerations with prolonged suppression, consistent with findings from aromatase-deficient models. Many patients describe diminished overall response to therapy when estradiol is over-suppressed relative to balanced, symptom-guided management.
Over-reliance on these agents without individualized assessment can therefore exchange one set of issues for others, particularly affecting long-term skeletal integrity and daily comfort.
Approaches to Balanced Management
Individual responses depend on age, body composition, dose, injection frequency, and genetics. Regular evaluation of laboratory values (estradiol assays) together with symptom tracking supports adjustments focused on the patient’s experience rather than automatic blocker use. Some men maintain suitable ratios with little intervention; others need only occasional, low-dose management when high-estradiol symptoms emerge.
For men seeking providers who emphasize symptom tracking alongside comprehensive laboratory evaluation rather than default aromatase inhibitor protocols, telehealth services such as those offered through Vita Bella provide consultations centered on individualized hormone management.
When peptide options are considered alongside hormone protocols for tissue support or metabolic goals, platforms like Vita Bella can connect patients with supervised programs that integrate testing and follow-up adjustments.
References:
de Ronde W, de Jong FH. Aromatase inhibitors in men: effects and therapeutic options. Reprod Biol Endocrinol. 2011;9:93. doi:10.1186/1477-7827-9-93.
Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011-1022. doi:10.1056/NEJMoa1206168.
Shigehara K, Izumi K, Mizokami A, Namiki M. Testosterone and bone health in men: a narrative review. J Clin Med. 2021;10(3):530. doi:10.3390/jcm10030530.
Cauley JA. Estrogen and bone health in men and women. Steroids. 2015;99(Pt A):11-15. doi:10.1016/j.steroids.2014.12.010.
Rochira V, et al. Estrogens, male reproduction and beyond. In: Endotext. MDText.com; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK278933/.
